3FRG
Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Quinoline Inhibitor
Summary for 3FRG
| Entry DOI | 10.2210/pdb3frg/pdb |
| Related | 1F0J |
| Descriptor | cAMP-specific 3',5'-cyclic phosphodiesterase 4B, 4-[(3-methoxyphenyl)amino]-6-(methylsulfonyl)quinoline-3-carboxamide, ZINC ION, ... (7 entities in total) |
| Functional Keywords | pde, phosphodiesterase, camp, alternative splicing, hydrolase, phosphoprotein, polymorphism, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 41454.03 |
| Authors | Somers, D.O.,Neu, M. (deposition date: 2009-01-08, release date: 2010-01-12, Last modification date: 2023-09-06) |
| Primary citation | Lunniss, C.J.,Cooper, A.W.,Eldred, C.D.,Kranz, M.,Lindvall, M.,Lucas, F.S.,Neu, M.,Preston, A.G.,Ranshaw, L.E.,Redgrave, A.J.,Ed Robinson, J.,Shipley, T.J.,Solanke, Y.E.,Somers, D.O.,Wiseman, J.O. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg.Med.Chem.Lett., 19:1380-1385, 2009 Cited by PubMed Abstract: Crystallography-driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of a series of quinoline derivatives that were highly potent and selective inhibitors of PDE4 with a good pharmacokinetic profile in the rat. Quinolines 43 and 48 have potential as oral medicines for the treatment of COPD. PubMed: 19195882DOI: 10.1016/j.bmcl.2009.01.045 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.7 Å) |
Structure validation
Download full validation report
